Dr. Emanuel Petricoin, III
Scientific Advisory Board
Dr. Petricoin is one of the inventors of the Nanotrap® technology. As a member of the Ceres Scientific Advisory Board, Dr. Petricoin provides technical guidance and expertise to key components of Ceres Nanosciences' operations. Dr. Petricoin is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. Dr. Petricoin formerly worked with the FDA where he was the senior investigator in the Office of Cell Tissue and Gene Therapies in the Center for Biologics Evaluation and Research. Dr. Petricoin holds a doctorate in microbiology from the University of Maryland at College Park. Together with Dr. Lance Liotta, he has formed the Center for Applied Proteomics and Molecular Medicine. The Center has formed a unique partnership between George Mason and Inova Health System. George Mason University-Inova Health System Translational Research Centers is a joint initiative to coordinate multiple programs to implement proteomics, nanotechnology, and genomics research in cancer, metabolic syndrome, cardiopulmonary diseases, and neurodegenerative and liver diseases. This initiative comprises the research efforts of three shared centers: the Center for Applied Proteomics and Molecular Medicine; the Center for Biomedical Genomics; and the Center for the Study of Genomics of Liver Diseases. Inova and George Mason have combined efforts to recruit internationally renowned scientists, such as Dr. Liotta and Dr. Petricoin, to work closely with clinical investigators from Inova.

Dr. Lance Liotta
Scientific Advisory Board
Dr. Liotta is one of the inventors of the Nanotrap® technology. As a member of the Ceres Scientific Advisory Board, Dr. Liotta provides technical guidance and expertise to key components of Ceres Nanosciences' operations. Dr. Liotta is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. He was formerly the Chief of the Laboratory of Pathology at NCI's Center for Cancer Research, where he also served as the chief of the center's Tumor Invasion and Metastases section, Deputy Director for Intramural Research, Co-Director, NCI/FDA Clinical Proteomics Program, and chairs the National Institutes of Health Radiation Safety Committee. He earned his medical degree from Case Western Reserve Medical School and also holds a doctoral degree in biomedical engineering from Case Western Reserve University. Dr. Liotta and Dr. Petricoin began their proteomics collaboration in 1997, which led to the formation of the first Interagency Agreement between NCI and FDA to develop and test technologies for proteomic analysis—the study of protein activity in cells—of cancer and other diseases. Their renowned collaboration has produced more than 100 publications and numerous proteomic processes to develop new methods for diagnosis and treatment of diseases. Combining their clinical and research expertise, they invented a new type of protein microarray technology to simultaneously measure multiple protein pathways from a biopsy specimen. Understanding the activity of protein pathways may ultimately lead to personalized medical treatment and significantly impact public health. In addition to their invention and development of new types of protein microarray technologies, they recently have made several seminal discoveries for biomarker-based research that may assist in the diagnosis of cancer and other diseases.